190 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
-201, the expected benefits to LUM-201, and any other statements other than statements of historical fact. We wish we were able to predict the future … repartitions visceral fat to the periphery and increases muscle mass Obtain weight loss benefits from GLP-1 with body composition and metabolic benefits of GH
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
enrich trials for patients likely to respond to LUM-201, the expected benefits to LUM-201, and any other statements other than statements of historical
8-K
EX-99.2
u5vtdy7m28
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
3kmf1tknnan3d20bxp3
15 Nov 23
Other Events
4:38pm
8-K
EX-99.1
rs901
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.2
fuxrgb7w
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
424B5
scf7vuex43 1unu
29 Aug 22
Prospectus supplement for primary offering
5:14pm